https://www.selleckchem.com/pr....oducts/ly2584702.htm
Among 36 healthy volunteers enrolled in the study (FluCyD-vac, n=24; Flu-vac, n=12), FluCyD-vac was well tolerated. Most of the solicited AEs were mild local skin reactions at the injection site. No serious AEs were reported in either group. HI titers 21days after vaccination with FluCyD-vac were comparable with those of Flu-vac and sufficient to meet international criteria, despite reduced HA antigen doses. When PBMCs were stimulated with the four HA antigens in the vaccine, tumor necrosis factor (TNF)-α-producing CD4 T cells were en